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The limited lifetime of neural implants continues to frustrate the progress of neuroscience 
research.  Despite extensive research into the inflammatory process and the encapsulation 
cascade, there has been little attention to when functional degradation of the neural probe 
actually begins.  However, the initiation point is critical in determining the optimal time 
to intervene in the encapsulation process.   If onset of signal degradation occurs at the 
very early stages of encapsulation, inhibition agents could be introduced to prevent glial 
activation.  On the other hand, if onset occurs later in the encapsulation process it might 
be more advantageous to interrupt the inflammatory process before the formation of scar 
tissue.  To answer these questions, we developed in vitro models for injury 
(thrombin/scratch) and acute inflammatory response (lypopolysaccride, LPS) to 
investigate the correlation between increasing signal impedance and the activation of 
xxii 
glial cells.  Using these in vitro models to monitor the impedance of the activated cells, 
we were able to demonstrate the increased impedance of activated glial cells compared to 
inactivated cells.  This finding suggests that once an optimal strategy to intervene in 
encapsulation is developed, it should be possible to get stable long term 
recording/stimulation by controlling encapsulation at acceptable levels.  We proved this 
concept of dynamic control, testing sequential activation/deactivation of glial cells to 
investigate: 1) if controlling glial activation levels over a short period of time is possible, 
and 2) the effect of the change of the activation levels on probe functionality by 
monitoring impedance.  The critical implications of our results are that glial activation 
can be controlled in short periods of time and, hence, the impedance of the probe can be 
controlled by controlling the activation of the glial cells surrounding the probe. 
1 
CHAPTER I 




Neural probes have been widely used to restore brain function through applications 
such as deep brain stimulation (Obeso, Guridi et al. 2001) and brain computer interfaces 
(Nicolelis 2001; Wolpaw, Birbaumer et al. 2002; Kipke 2004).  However, the 
unpredictable lifetime of the implanted neural probe has proved a challenge for many 
promising clinical applications (Normann 2007).  The functional degradation of a neural 
probe, it has been hypothesized, is caused by probe encapsulation, which is an 
inflammatory response to the probe insertion (Agnew, Yuen et al. 1986; Grill and 
Mortimer 1994).  Considerable efforts have been put into increasing longevity of the 
neural probe through drug delivery (Spataro, Dilgen et al. 2005), improved probe 
materials (Rousche, Pellinen et al. 2001), or coatings (Ludwig, Uram et al. 2006).  
However, maintaining prolonged probe functionality has continued to be a problem.  
The encapsulation of neural probes essentially consists of a sheath that is made of 
microglia and astrocytes.  The astrocytes surround the clustered microglia in an 
encapsulation layer.  This sheath of reactive tissue, called a “glial scar”, is a chronic 
feature of the implant.  The thickness of the sheath decreases over time but becomes 
denser, making a complete glial scar (Schultz and Willey 1976; Edell, Toi et al. 1992; 
Turner, Shain et al. 1999).  Researchers in the 1980’s and 90’s already suspected that 
glial scarring is responsible for the reduced electrical signal conduction observed over 
time (Agnew, Yuen et al. 1986; Grill and Mortimer 1994).   
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Early studies had already determined that the formation of the glial scar is created 
in two stages: the early acute response to the mechanical injury from insertion 
(Fig.1.1(a)), and the sustained chronic response which results in the glial scar (Fig.1.1(b)) 
(Szarowski, Andersen et al. 2003).  The early acute response is initiated by the secretion 
of the proinflammatory cytokines secreted by glial cells secondary to the injury caused by 
neural probe insertion (Dinarello 2000).  These proinflammatory cytokines recruit other 
glial cells around the inserted neural probe, activating them.  The glial scar is then formed 




Fig.1.1. Cartoons demonstrating cellular responses during early (a) and chronic (b) 
reactive responses.  (a) In the early inflammation response, microglia and macrophages 
migrate into the lesion, secreting various cytokines and growth factors while also 
removing necrotic tissue. Activated astrocytes form a physical barrier around the area of 
tissue damage, protecting the residential neurons outside the wound from further insult. 
Inhibitory molecules associated with myelin and produced by astrocytes within the glial 
scar block regeneration of damaged axons.  (b) In the sustained chronic response, the 
fibrin clot and necrotic tissue is removed by microglia and macrophages. Unlike 
nonneural tissue, lost tissue is not replaced, leaving a lesion with a cerebral spinal fluid– 
filled cyst. Astrocytes become denser surrounding the cyst to form a glial scar, protecting 
the uninjured tissue from further injury (modified from 
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=frimp&part=ch1) 
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If signal loss could be established in the acute phase, then effective intervention 
would consist of preventing glial activation, whereas if it occurs in the chronic phase, 
intervention would have to focus on disrupting the process of scar formation.  To 
determine when the dominant signal loss begins, we investigated if activation at the early 
stages increases impedance or not, and, if so, at what point.  We tested the hypothesis that 
activated glial cells surrounding the neural probe increase the impedance and signal loss. 
 In addition to the mechanical injury associated with in vivo neural probe insertion, 
it has been hypothesized that glial cell activation is due to the rupture of small blood 
vessels which leads to intra-cerebral micro-hemorrhages, bleeding into the extracellular 
matrix (ECM) of the brain (Power, Henry et al. 2003; Pekny and Nilsson 2005; Polikov, 
Tresco et al. 2005; Viswanathan and Chabriat 2006).  When a neural probe is inserted in 
the brain tissue, the probe 1) damages glial and neuronal cell processes, and 2) 
unavoidably ruptures the micro vasculature of the brain, which is very dense (Bjornsson, 
Smith et al. 2004).  Until the damaged vasculature has been restored, there is a large 
influx of thrombin, as well as other blood components, into the extra cellular matrix of 
the brain tissue. 
 Thrombin, a serine protease, is immediately produced in the brain after 
intracerebral hemorrhage, brain trauma, or the breakdown blood–brain barrier after brain 
injury (Jiang, Wu et al. 2002).  Thrombin stimulates a variety of cells, such as, 
endothelial cells, neuronal cells, monocytes/macrophages, smooth muscle cells, 
fibroblasts, platelets and lymphocytes, most of which are important for tissue repair 
(illustrated in Fig.1.2) (Goldsack, Chambers et al. 1998).  Although the trigger 
mechanism for cytokine secretion is unknown, it is hypothesized that thrombin induces 
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the cytokine secretion by microglia and astrocytes, initiating inflammatory cascade (see 
Fig.1.3) with the ensuing formation of glial encapsulation (Suo, Citron et al. 2004).   
We were interested in investigating at which point in the encapsulation process 
signal loss is initiated: at the early inflammation stage or the later scar formation stage.  It 
is important to identify the initiation point in order to determine the optimal time to 
intervene in the encapsulation process.  To test the hypothesis that activated glial cells 
surrounding the neural probe in the acute phase increase the impedance and signal loss, 
we decided to test whether impedance increases during glial activation.  To do so in vitro, 
however, required that we develop a comparable in vitro model that would allow us to 
activate glial cells (astrocytes and microglia) plated on a microelectrode and monitor for 
electrical impedance across the plated cell layers.  We then had to develop a way to 
activate the astrocytes and microglia so that we could determine the impedance increase 
due to activation.  This required establishing an adequate control group as well as 
measuring impedance before and after activation of the experimental group. 
Once an optimal strategy to intervene in encapsulation is developed, it should be 
possible to get stable long term recording/stimulation.  We suspect that this optimal 
strategy will involve dynamic control, i.e., controlling encapsulation levels in an 
acceptable range.  To demonstrate the proof of concept for this control of encapsulation 
level dynamically for the self-repairing neural probe (SRNP), we opted to test sequential 
activation/deactivation of glial cells over a short period of time.  For each step of the 
activation/deactivation stage, we would investigate the effect of the change of the 
activation levels on the probe functionality by monitoring the trans-cellular impedance of 
the activated/deactivated glial cells. 
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Fig.1.2. Thrombin stimulates variety of cells, activating them, most of which are 
important for tissue repair (Goldsack, Chambers et al. 1998). 
 
 
Fig.1.3. Schematic illustration of potential sources of active thrombin in the CNS and its 
regulation on the injury caused by neural probe insertion 
6 
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GLIAL CELL ACTIVATION RESULTING FROM TISSUE INJURY: 
AN IN VITRO MODEL 
 
1. Introduction 
Encapsulation was first modeled by Merrill and Tresco who built an in vitro 2D cell 
culture chamber and used the electrical impedance of the surrounding tissue as a measure 
of encapsulation (Merrill and Tresco 2005). Encapsulation was then modeled by 
Frampton and Shain who built an in-vitro 3D cell culture model mimicking high cell 
density as found in the brain (Frampton, Hynd et al. 2007). Both studies demonstrated 
that electrical impedance increased when a neural probe was encapsulated by plated glial 
cells in vitro. 
We wanted to further investigate glial encapsulation focusing on the activation level 
of glial cells in terms of impedance and recorded signal quality.  It is well known that 
glial activation induces cytokine secretion, increases intercellular adhesion and 
proliferation, and changes the morphology of glial cells. To investigate this relationship, 
we needed a tissue injury model that could provide glial activation.  A good in vitro 
tissue injury model should be able to activate glial cells with a method close to in vivo 
tissue injury and confirm the activation.   
Since current encapsulation models do not distinguish between activated and non-
activated glial cells, we designed a novel tissue injury model simulating both mechanical 
12 
injury and the micro-hemorrhages caused by blood vessel rupture to differentiate between 
two levels of glial cell activation.  A scratch was made on a co-cultured monolayer of 
mouse astrocytes and microglia to simulate the mechanical tissue injury (Polikov, Block 
et al. 2006). In addition, thrombin was introduced to the culture media to simulate the 
microhemorrhages resulting from the blood vessel ruptures during neural probe insertion 
(Suo, Citron et al. 2004).  Thrombin was included in our model because just scratching a 
cell layer does not simulate micro-hemorrhages since the cultured cells do not include 
blood vessels.  The glial activation was confirmed by demonstrating morphological 





To mimic the impact of the neural probe insertion, we employed two models: injury 
and acute inflammation.  The injury model has four components: glial cells, a neural 
probe, thrombin and scratch.  The glial cells that were to be activated for the injury model 
were prepared from the brain of newborn mice using a modified Suzumura protocol 
(Suzumura, Bhat et al. 1984).  The silicon based neural probe was included in the injury 
model to mimic the environment of neural probe insertion.  An actual recording electrode 
without a printed circuit board (PCB) was used.  Glial cells were then plated on the 
neural probe and subjected to either activation by thrombin/scratch (experimental) or no 
treatment (control).  On the other hand, the acute inflammation model has three 
components: glial cells, a neural probe and lipo-polysaccharide (LPS), a component of 
the outer membrane of gram-negative bacteria. LPS was applied to the glial cells in the 
culture to activate the cells. 
 
2.1. Experimental setup 
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL 
streptomycin (Invitrogen, Rockville, MD). Medium was changed every 3-4 days. This 
mixed culture mainly contained astrocytes and microglia.  These cells were allowed to 
grow and proliferate for 2-3 weeks based on the state of confluence and then plated on a 
24-well tissue culture plate.  Each plated well had a dummy silicon electrode placed on 
the bottom.  All experiments and animal care were performed in accordance with the 
University Committee on Use and Care of Animals (UCUCA) guidelines. 
14 
Before plating cells, the setup was sterilized by UV light for 1 hour.  To enhance 
the cell attachment, the bottom of the well, where cells were to be plated was coated with 
fibronectin solution from bovine plasma (5 µg /cm2, Sigma-Aldrich, Inc. St. Louis, MO) 
and then the setup was dried under a sterile hood for 45 minutes at room temperature.  
Mixed cells were plated on the well at a density of 2x105 cells per well (2 cm2).   
The groups of plated cells were allowed to settle and become confluent for 48 hours 
in 10% fetal bovine serum (FBS) media and then each group was subjected to either 
activation by thrombin/scratch (experimental) or no treatment (control).  For the 
experimental group, a mechanical scratch was made on the confluent glial cell layer 
along the shank of the neural probe using a sterile 31-gauge syringe needle and the cells 
were then supplied with 5 NIH U/mL of thrombin from bovine plasma (Sigma-Aldrich, 
Inc. St. Louis, MO) in a 1% FBS culture media (see chapter 2 for more details).  The 
control group received only 1% FBS culture media and was not subjected to thrombin or 
mechanical scratch. 
 
2.2. Verifying that the neural probe material does not activate glial cells 
To verify our plated cells had not been activated by the probe material prior to our 
experiment, we tested if the probe material induces increased cytokine secretion.  Our 
rational for this test was that if the probe material activates cells, we had to be able to 
differentiate material induced activation from the injury (thrombin/scratch) induced 
activation.   
 To determine if cytokines had been secreted in response to the probe material, we 
plated one group of cells on silicon probes placed on the bottom of the wells of a 24-well 
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cell culture plate.  Each well contained only one silicon neural probe.  The control group 
was plated in the same manner but in wells that did not include silicon probes.  The glial 
cells were plated on the surface of all wells and allowed to settle for 48 hours in 10% 
FBS media.  Then 10% FBS media was removed and supplied with 2% FBS media with 
0.5xAnti-anti media.  The media were collected at different time points (30 min, day 1, 
day 7 and day 13) and analyzed by RayBio Mouse Cytokine Antibody Array (Ray 
Biotech Inc., Norcross, GA) and by ELISA (SABiosciences, Frederick, MD) to quantify 
the cytokines secreted at different time points. 
 
2.3. Activation of glial cells in the experimental setup 
2.3.1. Activation by thrombin  
To find the optimum concentration of thrombin for activation of glial cells, we 
tested three different concentrations of thrombin in cell culture media with four different 
serum concentrations.  The efficacy of different thrombin concentrations was determined 
by the degree of morphological change of the glial cells.  The optimum condition should 
make the biggest morphological change while making maximum contrast between 
thrombin concentrations in the same FBS concentration.  If the FBS concentration were 
too high, it would be difficult to differentiate if the cells were activated by thrombin or 
FBS.  If the FBS concentration were too low, the cells might not have had sufficient 
nutrients for survival.   
Mixed brain cells were seeded in a 24 well plate with a density of 2x105 cells per 
each well.  After the culture became confluent, cells were washed twice with PBS and 
DMEM with 250 µM of dibutyryl-cAMP (dbcAMP, Sigma-Aldrich, Inc. St. Louis, MO) 
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was applied to the cells for 24 hours.  The cells were then washed twice with PBS and 
subsequently treated with three different concentrations of thrombin (0.1, 5, and 30 NIH 
U/mL) in four different cell culture media with different fetal bovine serum (FBS) 
concentrations (0, 0.1, 1, and 10%).  In total, we prepared 12 different treatment 
conditions.  Cell morphologies were observed using phase contrast microscopy. 
 
2.3.2. Activation by scratch 
To mimic the mechanical injury caused by the neural probe insertion, and the 
thrombin release resulting from the ensuing micro-hemorrhage, we made a 5mm long 
scratch on the confluent glial cell layer running a sterile 31-gauge syringe needle along 
the neural probe, and 5 NIH U/mL of thrombin from bovine plasma (Sigma-Aldrich, Inc. 
St. Louis, MO) in 1% FBS culture media was supplied to the cells.  Only culture media 
with 1% FBS was supplied for the control group with no thrombin or mechanical scratch. 
 
2.3.3. Activation by acute inflammation  
To mimic the acute inflammatory response introduced by the neural probe insertion, 
we used LPS (10 µg/mL in 1% FBS media) as an activation agent.  
 
2.4. Detection of activated glial cells in the experimental setup 
We wanted to confirm that glial cells are activated by the injury (thrombin/scratch) 
and the acute inflammation (LPS) model.  To confirm the presence of activation, we 




2.4.1. Morphological change 
The degree of activation produced by thrombin was determined by the 
morphological change of glial cells using phase contrast microscopy (Nelson and Siman 
1990).  First, glial cells were deactivated in dbcAMP (1mM in 0% FBS media) for 24 hrs 
and then activated by applying thrombin (5 NIH U/mL in 0% FBS media) for 24 hrs.  
The cultures were photo documented under microscopy before and after glial activation. 
 
2.4.2. PAR-1 expression 
In addition to observing morphological changes, we also used the expression of 
protease-activated receptor 1 (PAR-1) to confirm the glial activation by thrombin.  The 
introduction of thrombin to glial cells activates PAR-1, which in turn initiates the 
activation of glial cells.  PAR-1, a seven transmembrane domain G-protein–coupled 
receptor, is activated by proteolysis from thrombin binding (Fig.2.1) (Coughlin and 
Camerer 2003; Nicole, Goldshmidt et al. 2005).   
Cells were plated on 24 well plates with 1% FBS culture media and subjected to 
one of six different conditions: 1) control cells without  neural probe and treatment 
(control 1), 2) control cells on a neural probe but no treatment (control 2), 3) cells on a 
neural probe with thrombin (5 NIH U/mL), 4) cells on a neural probe with thrombin (5 
NIH U/mL) and scratch, 5) cells on neural probe with LPS (10 µg/mL, control 3), and 6) 
cells on neural probe with TNF-alpha (10 ng/mL) and IL-1beta (10 ng/mL, control 4).  In 
addition to controls 1 and 2, controls 3 and 4 were added to confirm that PAR-1was not 
expressed without thrombin.   
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Samples were fixed at different time points (days 1 and 5) and stained.  Cultures 
were washed with PBS, fixed with prechilled (4°C) 5% acetic acid in methanol for 45 
min at 4°C, and followed by washing with PBS. Samples were blocked with 10% BSA in 
PBS for 1 h at 25°C and then incubated with primary antibodies against PAR-1 (1:100, 
Santa Cruz Biotechnology Inc., Santa Cruz, CA) in PBS containing 5% BSA and 0.1% 
Tween-20 for 2 h at 25°C or overnight at 4°C. After washing with PBS containing 1% 
BSA and 0.1% Tween-20, samples were incubated with secondary antibodies (1:200, 
Santa Cruz Biotechnology Inc. Santa Cruz, CA) at room temperature for 1 h followed by 
washes. After staining, samples were mounted with Prolong gold, an antifade, and 
observed under a microscope. 
 
Fig. 2.1. Mechanism of PAR-1 activation.  PAR-1, a seven transmembrane domain G-
protein–coupled receptor, is activated by proteolysis from thrombin binding from 
(Coughlin and Camerer 2003) 
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2.4.3. Detection of expressed cytokines using protein array 
Our third method to confirm glial activation used a protein array to detect the up 
regulated inflammatory cytokines secreted when glial cells are activated.  Cells were 
plated on 24 well plates in 1% FBS culture media and subjected to one of four different 
conditions: 1) cells without neural probe or treatment (control 1), 2) cells plated on neural 
probe without treatment (control 2), 3) cells on neural probe with thrombin (5 NIH 
U/mL), and 4) cells on neural probe with LPS (10 µg/mL).  Culture media and cell 
lysates were collected at different time points (days 1 and 5) and analyzed separately (16 
total samples) using RayBio Mouse Cytokine Antibody Array (Ray Biotech Inc., 
Norcross, GA) and ScanAlyze software (Eisen Lab, Berkeley, CA). 
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3. Results 
Our results demonstrated that glial cells were well plated on the electrode in the 
experimental setup and successfully activated.  We were able to create both injury 
(thrombin/scratch) and acute inflammation (LPS) models that mimic the in vivo 
conditions of neural probe insertion associated with glial activation.  The activation 
observed in our models confirmed the results of previous studies, i.e., that the glial 
activation induces morphological change and up-regulated inflammatory cytokine 
expression. 
 
3.1. Cultured cell layer in the experimental setup 
Mixed culture of mice astrocytes and microglia were well plated on the electrode as 
well as on the bottom surface in the experimental setup (Fig.2.2).  Immunohistochemical 
staining showed plated cells on the electrode and on the bottom of the well surface: 
Green for astrocyte cell body (GFAP counter staining), red for microglia (Iba-1), and 
blue for all nuclei (Hoechst). 
   
Fig.2.2. Immunohistochemical staining confirmed that cells microglia and astrocytes 
were successfully plated in the experimental setup.  GFAP for astrocytes was stained in 
red, Iba1 for microglia in green, and Hoechst for all cell nuclei. 
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3.2. Verifying that the neural probe material does not activate glial cells 
Glial cells were not activated by the material of the neural probe itself. Protein array 
(Fig.2.3) and ELISA (not shown) test results indicated that there was no difference in the 
amount of secreted cytokines between experimental cells on a neural probe and the 
control cells. We can deduce that the reactive tissue reaction around the neural probe 
insertion site may be caused by the injury due to the probe insertion not by the material of 
the probe. This result is in accordance with in vivo result that just one of two adjacent site 
showed large reactive reaction whereas another site showed very minimal reaction 
(Rousche and Normann 1998). 
 
Fig.2.3. Normalized amount of inflammatory cytokines expressed in the cells with a 
probe at the bottom (experimental) to the control without a probe.  Supernatant were 
collected at different time points (30min, days 1, 7, and 13) and analyzed by a protein 
array.  
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3.3 Thrombin concentration test 
Cells subjected to 5 NIH U/mL of thrombin (Fig.2.4, second column from left) 
showed the greatest morphological change.  Cells subjected to 1% FBS media (Fig.2.4, 
third row from the top) were not only viable, but also showed clear differentiation 
between the morphological changes caused by thrombin and those caused by FBS.  
Therefore, we decided to use 5 NIH U/mL of thrombin in 1% FBS for our 
thrombin/scratch model.   
Please note that cells subjected to 10% FBS media (Fig.2.4, fourth row from the top) 
were viable as well.  However, it was hard to determine the difference in morphologies 
between different thrombin concentrations.  Cells in all three groups (0.1, 5 and 30 NIH 
U/mL of thrombin) were flat probably because high serum contents activated cells.  In 
this case, it is hard to differentiate the effect of thrombin on glial activation.  Therefore, 
we decided not to use 10% FBS media. 
23 
 
Fig.2.4. Phase contrast microscopic pictures of thrombin concentration test.  Four 
different serum concentrations (0, 0.1, 1 and 10%) and three different thrombin 
concentrations (0.1, 5 and 30 NIH U/mL) were used.  Each rows had same FBS 
concentration and each column had same thrombin concentration.  Cells were deactivated 




3.4. Detection of glial activation 
3.4.1. Morphological change 
Thrombin (in 10% FBS), LPS (in 10% FBS) and 10% FBS all induced 
morphological changes in glial cells, as shown in Fig.2.5.  Fig.2.5(a) shows the cells prior 
to thrombin treatment (5 NIH U/mL) and (b) shows cells 24 hrs post thrombin treatment.  
Adding thrombin (5 NIH U/mL in 0% FBS media) to the cells pretreated with dbcAMP 
(1mM in 0% FBS media for 24 hrs) induced morphological change from stellate to flat.  
Adding LPS (10 µg/mL in 10% FBS media) to the cells in dbcAMP (1mM in 0% FBS 
media) for 24 hrs also induced morphological change from stellate to flat.  However, 
control group, adding 10% FBS media to the cells was in 0 dbcAMP (1mM in 0% FBS 
media) for 24 hrs, also induced the same change and there was no difference between 
these two groups.   
 
3.4.2. PAR-1 expression 
PAR-1 expression was not different between experimental and control groups 
indicating that activated PAR-1 was not detected more in experimental group.  In all 
groups, PAR-1 was not as highly expressed (figure not shown).  This low expression of 
the activated PAR-1 may be due to rapid internalization and subsequent degradation in 




Fig.2.5. Glial cells were (a) treated in dbcAMP (250 µM in 0% serum for 24 hrs) to 
achieve stellate shape and then subjected to one of three conditions: (b) thrombin (5 NIH 
U/mL in 0% FBS media), (c) LPS (10 µg/mL in 10% FBS media), and (d) 10% FBS 
media.  All three groups induced morphological changes.  Specifically, there is no 
difference between (c) and (d). 
 
 
3.4.3. Inflammatory cytokines 
As expected, a greater amount of inflammatory cytokines were expressed in the 
injury (thrombin/scratch) and the acute inflammation (LPS) models compared to the 
control.   
Fig.2.6 and Fig.2.8 shows the cytokines expressed on days 1 and 5 of the injury 
(thrombin/scratch) model and Fig.2.7 and Fig.2.9 shows the cytokines expressed in the 
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acute inflammation (LPS) model.  To compare the relative expression of the cytokines 
experimental and control groups, we normalized the expression of experimental group to 
the control. (Fig.2.7 for thrombin/scratch and Fig.2.9 for LPS).  This normalized 
expression indicated which cytokines were expressed more (by more than 50%) in the 
experimental group than in the control group.  On day 1, 6Ckine, GM-CSF, IL-2, IL-4, 
IL-5, IL-6, IL-9, IL-10, IL12-p40/p70, IL12-p70, IL-13, IFN-gamma, KC, MCP-1, MIP-
1-alpha, MIP-3-beta, RANTES and TNF-alpha were expressed more in the injury 
(thrombin/scratch) group than the control group (by more than 50%, see Fig.2.6).  On day 
5, 6Ckine, GM-CSF, IL-9, IL-10, IL12-p40/p70, IL12-p70, IL-13, IL-17, IFN-gamma, 
KC, MCP-1, MIP-1-alpha, MIP-3-beta, RANTES, sTNF RI, TARC, TNF-alpha, TPO 
and VEGF were expressed more in the injury (thrombin/scratch) group than the control 
group (by more than 50%, see Fig.2.8).  IL-6 and TNF-alpha, major proinflammatory 
cytokines were expressed 2 fold more in the injury (thrombin/scratch) model than the 
control on day 1.  TNF-alpha was expressed 9 fold more on day 5.  IL-5 was expressed 6 
fold more on day1 but was not expressed more on day 5.  Please note that (1) IL-5 and 
IL-6 were more expressed on early stage (day 1) than on later stage (day 5), and (2) GM-
CSF, IL-10, IL12-p70, MIP-1-alpha, RANTES and TNF-alpha were more expressed on 
both early stage (day 1) and later stage (day 5) (see Fig.2.10(a)).  These temporal trends 
of cytokine expression correspond to the in vivo trend during cerebral wound healing 
using a traumatic brain injury model as shown in Fig.2.10(b) (Takamiya, Fujita et al. 
2007).  Not only proinflammatory cytokines but also antiinflammatory cytokines, such as, 
IL-10 and IL-13 were expressed more in the injury (thrombin/scratch) model.  The 
antiinflammatory cytokines modulate the inflammation process or decrease the intensity 
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of the inflammation cascade.  These pro- and anti-inflammation cytokines always 
expressed together with different level.  The outcome of a disease is determined by the 
balance between these two cytokines (Dinarello 2000).  Therefore the higher expression 
of IL-10 and IL-13 should be understood in the context of the balance of the cytokines. 
For the acute inflammation (LPS) model, CTACK, GM-CSF, IL-4, IL-5, IL12-
p40/p70, IL12-p70, IL-13, KC and RANTES were expressed more in the acute 
inflammation (LPS) group than the control group (by more than 50%, see Fig.2.9).  On 
day 5, 6Ckine, CTACK, Eotaxin, G-CSF, GM-CSF, IL-2, IL-3, IL-4, IL-10, IL12-
p40/p70, IL12-p70, IL-13, IL-17, IFN-gamma, KC, Leptin, MCP-1, sTNF RI, TARC, 
TNF-alpha, TPO and VEGF were expressed more.  In the acute inflammation (LPS) 
model, the temporal cytokine expression trend was not observed as was found in the 





Fig.2.6. Inflammatory cytokines expressed in the injury (thrombin/scratch) group.  Cells 
of the injury group (experimental) were treated with thrombin (5 NIH U/mL) and a 
scratch was made on the cell layer.  Cell lysate samples were collected at days 1 and 5, 
and analyzed by a protein array.  X-axis shows each cytokine at day 1 and day 5 and y-
axis indicates arbitrary number for expressed signal intensity.  Red bars are for the injury 
(thrombin/scratch) group and black bars for the control, which had the same condition 
(cells on a probe) but no treatment. 
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Fig.2.7. Inflammatory cytokines expressed in the acute inflammation (LPS) group.  Cells 
of the acute inflammation group (experimental) were treated with LPS (10 µg/mL).  Cell 
lysate samples were collected at days 1 and 5, and analyzed by a protein array.  X-axis 
shows each cytokine at day 1 and day 5 and y-axis indicates arbitrary number for 
expressed signal intensity.  Blue bars are for the acute inflammation (LPS) group and 




Fig.2.8. Normalized amount of inflammatory cytokines expressed in the injury 
(thrombin/scratch) group to the control.  Normalized values were calculated based on the 
same data shown in Fig.2.6.  Y-axis indicates folds of expression of the injury group 
compared to the control, which had the same condition (cells on a probe) but no treatment. 
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Fig.2.9. Normalized amount of inflammatory cytokines expressed in the acute 
inflammation (LPS) group to the control.  Normalized values were calculated based on 
the same data shown in Fig.2.7.  Y-axis indicates folds of expression of the injury group 
compared to the control, which had the same condition (cells on a probe) but no treatment. 
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Fig.2.10. Cytokine expression trends during: (a) our in vitro injury 
(thrombin/scratch) model and (b) in vivo cerebral wound healing using a traumatic brain 
injury model from (Takamiya, Fujita et al. 2007).  In (a), please note that (1) IL-5 and IL-
6 were more expressed on early stage (day 1) than on later stage (day 5), and (2) GM-
CSF, IL-10, IL12-p70, MIP-1-alpha, RANTES and TNF-alpha were more expressed on 
both early stage (day 1) and later stage (day 5).  These temporal trends of cytokine 
expression correspond to the in vivo trend in (b).  Please note that the time scale in this in 
vivo study could be different from the time scale in the in vitro model. 
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4. Discussion 
We proposed and verified a novel tissue injury model to activate glial cells, which 
simulates both mechanical injury and the micro-hemorrhage by the blood vessel rupture.  
This injury model was validated by confirming glial activation through demonstrating 
morphological change and up-regulated proinflammatory cytokines.  In addition, acute 
inflammation model using LPS was characterized by the same protocol.  These models 
are expected to be used for further in vitro glial activation studies. 
Cellular activation of glial cells by the injury model (thrombin/scratch) and the 
acute inflammation model (LPS) was confirmed by up-regulated inflammatory cytokine 
secretion (Fig.2.6, 2.7, 2.8 and 2.9).  Cytokines are low molecular weight glycoprotein 
that activates glial cells and also secreted by activated glial cells (Giulian, Woodward et 
al. 1988; Lieberman, Pitha et al. 1989; Sawada, Kondo et al. 1989).  Proinflammatory 
cytokines such as IL-1, IL-6, IFN-gamma and TNF-alpha are up-regulated at the site of 
injury in CNS and activates glial cells (John, Lee et al. 2003).  He et al. demonstrated that 
TNF-alpha is highly expressed in cells at the probe-tissue interface as shown in Fig.2.11 
(He, McConnell et al. 2007).  Biran et al. observed highly expressed TNF-alpha and 
MCP-1 from the glial cells of explanted microelectrode at 1 week post implantation 
(Biran, Martin et al. 2005).  These proinflammatory cytokines were also more expressed 
in the cells of our injury and acute inflammation models than in the control group 
confirming the glial cells in our model has been activated.  
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Fig.2.11. In situ hybridization of tissue sections from brain at 1 week post implantation.  
Arrows indicate TNF-alpha expressing cells (He, McConnell et al. 2007). 
 
Glial cells treated with thrombin/scratch also induced morphological changes.  In 
the injury (thrombin/scratch) group, cellular treatment by dbcAMP (Fig.2.5(a)) induced 
morphological change from flat into stellate as observed by Skaper et al. (Fig.2.12(b)) 
(Skaper, Facci et al. 1986) and by Nelson et al. (Fig.2.13(d)) (Nelson and Siman 1990) in 
rat astrocytes.  After treatment by thrombin (Fig.2.5(b)), cells changed their morphology 
from stellate into flat, similar to the cells treated by thrombin (Fig.2.13(e)) or kept in 10% 
FBS (Fig.2.13(a)) as observed by Nelson et al.  The morphological change by thrombin is 
mediated via Rho, a small GTP binding protein as demonstrated by Suidan et al.  
Thrombin also increases proliferation, expression of nerve growth factor (NGF) to 
promote the survival of astrocytes against environmental challenge (Suidan, Nobes et al. 
1997; Ramakers and Moolenaar 1998).  As shown in the literature survey by Suo et al., 
the effect of thrombin on astrocytes in vitro is dose dependant (Suo, Citron et al. 2004).  
At low doses in the pM level, thrombin causes morphological change from stellate into 
flat and prevents cell death.  At high dose in the nM level, thrombin induces proliferation, 
up-regulation of inducible nitric oxide synthase (iNOS), proinflammatory cytokines and 
cell death of astrocytes (Jiang, Wu et al. 2002).  This dose dependant action of thrombin 
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on astrocytes was also shown in vivo.  Pretreatment of low dose thrombin protects 
astrocytes and neurons whereas high dose thrombin infusion or injury induced thrombin 
initiated inflammation and resulted in glial scar (Suo, Citron et al. 2004).  However, this 
dose-dependent action of thrombin is specific to the source of thrombin.  Experimental 
results from the Xi group demonstrated that 5 NIH U/mL rat thrombin but not human 
thrombin caused neuronal death of cultured rat cells (personal communication with Dr. 
Xi).  The dose of thrombin (5 NIH U/mL from bovine plasma) we used in our model was 
high enough to activate glial cells but not too high to induce the cell death of astrocytes 
and microglia. 
The results suggest that thrombin induced the morphological change in glial cells 
whereas the morphological change in the acute inflammation (LPS) group may be due to 
the high serum contents in the media.  As shown in Fig.2.14, Beecher et al. observed the 
flat shaped mouse astrocytes when cells were treated with 10% FBS for 12 hrs 
(Fig.2.14(a)) and stellate shaped cells in 0% FBS for 12 hrs (Fig.2.14(b)) (Beecher, 
Andersen et al. 1994).  Nelson also observed the same morphological trend in rat 
astrocytes (Nelson and Siman 1990). Please note, however, that LPS (1 µg/mL) induces 
morphological change from ramified to amoeboid as observed by Beck et al. in cultured 
mouse microglia (Fig.2.15).  They observed that microglia shows a ramified (resting), 
‘fried egg’-shaped (fully activated) or intermediate morphology (Fig.2.15(A), left, right 
and in the middle respectively).  From day 1 to day 7 after subculturing, about 90% of the 
cells represented the ramified (resting) and 10% the ‘fried-egg’-shaped (activated) type 
(Fig.2.15(B)).  After adding 1 μg/mL lipopolysaccharide (LPS), 34% of the cells revealed 
a ‘fried egg’-shaped morphology already within 3 h. Within 48 h, the ratio of cell types 
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completely reversed to just 6% ramified and 94% ‘fried egg’-shaped cells (see 
Fig.2.15(C)) (Beck, Penner et al. 2008). 
A future model may include both injury by thrombin/scratch and acute 
inflammation by LPS in the same setup because injury is accompanied by acute 
inflammation as shown in literature survey by Arvin et al. (Arvin, Neville et al. 1996).  
As Jones and Geczy demonstrated, IL-1 activity of guinea-pig macrophages was greatly 
increased by the presence of thrombin during the activation by LPS.  Although thrombin 
alone had no effect, inclusion of 1 mU/mL of thrombin with suboptimal levels of LPS 
produced a 200-fold increase in IL-I activity, and further increase was observed with 
increasing doses of thrombin (Jones and Geczy 1990). 
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Fig.2.12. Morphological change of astrocytes from flat (a) to stellate (b) shapes. 
Secondary astrocytes were treated for 24 hrs in serum free media and treated again in 
serum free media without (a) or with (b) 1 mM dbcAMP for another 24 h (Skaper, Facci 




Fig.2.13. Thrombin effects on glial differentiation. 20-day-old mixed glial cultures were 
incubated in basal medium plus additions listed below, and photographed after 1 h. (A) 
10% FBS; (B) 10% FBS+250 µM dbcAMP; (C) 0% FBS; (D) 0% FBS+250 µM 
dbcAMP; (E) 0% FBS+50 nM thrombin; (F) 0% FBS+50 nM thrombin+250 pM 
dbcAMP (Nelson and Siman 1990).  
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Fig.2.14. Serum effects on astrocyte morphology.  Mouse cortical astrocytes were treated 
for 12 hr in 10% serum media (a), or serum free media (b).  Cell treated in 10% serum 
were flat and cells treated in 0% serum was stellate (Beecher, Andersen et al. 1994). 
 
 
Fig.2.15. Morphology of microglia, (A), composite image of scanning electron 
micrographs of microglial cells at various stages of activation with 1 μg/mL LPS from 
non-activated (left cell, arborized) to fully activated (right cell, ‘fried egg’-shaped). (B) 
and (C), percentage of ramified (mean±S.E.M.) and ‘fried egg’-shaped (mean±S.E.M.) 
cells per coverslip depending on time in subculture (Beck, Penner et al. 2008). 
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EFFECT OF GLIAL CELL ACTIVATION ON THE IMPEDANCE 




Although the correlation of the full encapsulation and signal quality loss is well 
known empirically, we still had to determine which step of the encapsulation process 
decreases signal quality significantly.  Better understanding of signal quality loss will 
make it possible to devise better strategies to resolve the problem. 
We were interested in investigating at which point in the encapsulation process 
signal loss is initiated: at the early inflammation stage or the later scar formation stage.  It 
is important to identify the initiation point in order to determine the optimal time to 
intervene in the encapsulation process.  If it occurs at an early stage, we should focus on 
preventing glial activation by the thrombin influx caused by the blood vessel rupture.  If 
it occurs only at a later stage, we should focus more on how to disconnect the process 
between inflammation and scar formation.   
In vivo studies showed that there is a rapid increase in impedance between days 3 
and 7 post probe insertion (Vetter, Williams et al. 2004; Ludwig, Uram et al. 2006).  
Vetter et al. observed a significant impedance increase between weeks 0 and 1 of 177 
µm2-site size electrodes and weeks 0 and 2 of 312 µm2-site size electrodes (Fig.3.1).  
Ludwig et al. also observed a sharp increase of impedance between days 3 and 7 (Fig.3.2) 
accompanied with significant decrease in percentage of sites recording low- and high-
quality units (Fig.3.3).  This increase in impedance is believed to occur because of the 
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tight intercellular adhesion formed when astrocytes around the probe were activated by 
inflammation cascade rather than because of the glial scar, which usually is seen between 
two and four weeks post probe insertion (Turner, Shain et al. 1999; Szarowski, Andersen 
et al. 2003).  
 
 
Fig.3.1. Mean impedance values across all implanted probes over time. Data are 
grouped by the size of the recording sites. Time bars indicate the contribution 
from each animal. Dotted lines represent the average standard error within each 
array and the error bars represent the standard error between each array (from (Vetter, 





Fig.3.2. Average site impedances at 1 kHz over time. The electrodes were implanted in 
rat brains.  Impedances increased dramatically the third day after implantation, up to a 
maximum value at the one-week mark (from (Ludwig, Uram et al. 2006).  
 
Fig.3.3. Percentage of sites recording low- and high-quality units on a given day. (a) 
Units with SNR > 2. (b) Quality units with SNR > 4. Unit recordings tended to be 
unstable over the first two weeks after implantation.  During these two weeks, a 
noticeable drop in measurable units occurred on both PEDOT and control sites (from 





To investigate if the impedance increase is due to the activation of glial cells in the 
early inflammation stage, we tested the impedance increase during the glial activation. 
We prepared an in vitro setup, in which astrocytes and microglia cells were plated on the 
microelectrode, monitoring electrical impedance across the plated cell layers.  These 
astrocytes and microglia were activated by the injury model (thrombin/scratch) or the 
acute inflammation model (LPS) as described in chapter 2.  The impedance increase was 
monitored before and after activation and compared to the impedance across the glial cell 
layers without activation (control group).  
The second goal of this study is to develop a new in-vitro model that uses recorded 
signal quality to detect encapsulation and to investigate cellular encapsulation using the 
new model.  Detecting encapsulation by the recorded signal quality gives us more direct 
understanding of encapsulation because we can analyze which frequency component of 
the recorded signal is degraded by a specific type of encapsulation, i.e., encapsulation by 
early reactive response or sustained chronic response.  To test the signal conduction 
through the different thickness and tightness of the sheath, we used the the in vitro 
cellular encapsulation model described in chapter 2.  We have also developed an in vitro 
stimulating/recording setup to investigate the relationship between recorded signal 




To investigate the glial inflammation effect on the performance of the recording 
electrode, we developed a impedance monitoring setup using the in vitro glial activation 
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model described previously (chapter 2).  To create different levels of inflammation, we 
treated the cultured glial cells on the neural probes under three different conditions: 1) 
activation by the injury model (thrombin/scratch, experimental), 2) activation by the 
acute inflammation model (LPS, experimental), and 3) no treatment (control).  These 
three conditions were created to test the hypothesis that the tight encapsulation resulting 
from the proliferation, changes in morphology, and higher intercellular adhesion, 
characteristic of cellular activation, is responsible for the reduced performance of the 
neural probe.   
The activated conditions (experimental) represent the injury or the acute 
inflammation due to probe insertion.  The inactivated condition (control) represents the 
resting state of the glial cells.  The performance of the probe was determined by the 
measured electrical impedance.  
To investigate the cellular encapsulation effect on the performance of the recording 
electrode, we developed and validated an in vitro ‘stimulation/recording’ setup.  During 
the development process, we found that there were daily fluctuations in the recorded 
signal amplitude even without plated cells on the electrode.  Similar fluctuation was 
observed in the impedance measurements as well.  To eliminate these fluctuations, we 
employed a control electrode array (without plated glial cells) and linear regression 
model to provide a baseline value for the recorded signal and impedance.  Using the new 
setup, we could determine the net effect of cellular encapsulation on both recorded signal 
quality and impedance. 
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2.1. Glial activation effect on impedance 
2.1.1. Experimental setup 
Primary glial cells were isolated from fetal mouse brain and plated on a 75 cm2 
tissue culture treated flask as described in chapter 2.  These cells were allowed to grow 
and proliferate for 2-3 weeks based on the state of confluence and then plated on the 
experimental setup, which contains a recording electrode on the bottom of a well.  The 
setup was prepared for cell plating using the same protocol previously describes (see 
chapter 2 for details).  Mixed cells were plated on the well at a density of 2x105 cells per 
well (2 cm2).  They were allowed to settle and become confluent for 48 hours in 10% 
fetal bovine serum (FBS) media and then subjected to two different conditions for each 
setup: 1) activation by thrombin/scratch (experimental), and 2) no treatment (control).  
For the experimental group, a mechanical scratch was made on the confluent glial cell 
layer along the shank of the neural probe using a sterile 31-gauge syringe needle and 5 
NIH U/mL of thrombin from bovine plasma (Sigma-Aldrich, Inc. St. Louis, MO) in 1% 
FBS culture media was supplied to the cells (see chapter 2 for more details).  Only 1% 
FBS culture media was supplied for the control group with no thrombin or mechanical 
scratch. 
 
2.1.2. Neural probes 
Microfabricated neural probes (NeuroNexus Technologies, Ann Arbor, MI) with 16 
iridium electrodes (each with a surface area of 177 µm2) were mounted on the bottom of 
a cell culture treated Petri-dish to serve as a recording electrode.  A custom built 
polystyrene ring was mounted around the neural probe to provide a well to hold cell 
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culture media around the probe. The function of the well was 1) to confine glial cells just 
around the neural probe, and 2) to reduce the amount of the activation/deactivation agents 
(thrombin and LPS) required in the media.  Three electrodes were used to measure the 
impedance: working (microelectrodes), counter (platinum-iridium coil), and reference 
(miniature Ag/AgCl).  The counter and reference electrodes were inserted in the 
electrolyte on the well only when the impedance measurement was conducted. 
62 electrode sites in four independent conditions were used for the injury group 
(thrombin/scratch), 46 electrode sites in three independent conditions were used for the 
acute inflammation group (LPS), and 52 electrode sites in four independent conditions 
were used for the control group with cells but without treatment.  To confirm the baseline 
impedance is constant during the entire period of experiment, we monitored the 
impedance of the bare electrodes with no cells but in the same condition – coated with 
fibronectin, soaked in the same cell culture media, temperature and carbon dioxide level.  
 
2.1.3. Impedance measurement 
We conducted all the electrophysiological tests in an electrolyte of Hepes-buffered 
Hanks' saline (HBHS) maintaining the cells in a 37ºC and 5% carbon dioxide 
environment in a tissue culture incubator with electromagnetic shied by copper mesh.  
HBHS was chosen because basic buffered saline provides the most stable results for our 
micro scale electrodes compared to DMEM or culture media with serum.  Three 
electrodes were used to measure the impedance: working (microelectrodes), counter 
(platinum-iridium coil), and reference (miniature Ag/AgCl).  Eco Chemie Autolab 
Potentiostat and Frequency Response Analysis software (Metrohm USA Inc., Riverview, 
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FL) were used to measure impedance.  Impedance measurements were conducted on days 
1 and 5 after activation to match the time points of injury model (see chapter 2).   
The impedance was measured in a frequency sweep limited to the frequencies 
typical of in vivo recordings.  In vivo signal recordings are composed of two significant 
band widths: (1) local field potential (LFP) including alpha (8-12 Hz), beta (12-24 Hz), 
and gamma (24-70 Hz) bands and (2) neuronal spikes around 1 kHz.  To represent these 
bands, several frequencies were chosen for the impedance spectra: alpha (10 Hz), beta 
(16 Hz), gamma (47 Hz), and neuronal spikes (300, 650, 1000, 3000 and 5000 Hz). 
We took phase contrast microscopic pictures right before the impedance 
measurements to confirm that the cells were confluent and viable during the impedance 
measurements.   
 
2.1.4. Statistical analysis 
SPSS software package (SPSS Inc. Chicago, IL) was used to conduct student’s t-
test to compare means of experimental and control groups if they are significantly 
different. 
 
2.2. Glial encapsulation effect on signal recording 
2.2.1. Experimental setup 
The setup is composed of three major components: a stimulator, a test chamber 
(Petri dish setup) and a recording system. The stimulator transmits electrical signals 
mimicking in vivo neuronal spikes to the stimulation electrodes in the test chamber (a 
Petri-dish setup) filled with phosphate-buffered saline (PBS).  In the test chamber, the 
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signal is propagated in the PBS, received by the recording electrode and then processed.  
Glial cells were plated on the recording electrode to model cellular encapsulation in vitro. 
With the in vitro model in the chamber, electro-physiological (EP) tests were performed 
in order to investigate the relationship between the recorded signal quality and the 
encapsulation.  Two types of EP tests were conducted: 1) signal quality analysis using the 
stimulation/recording setup and 2) impedance measurements. 
Recording electrodes consisted of two microelectrode arrays (NeuroNexus, Ann 
Arbor, MI); one for the experimental group and the other for the control group.  Each 
electrode array has 16 electrodes in line made of iridium with 100 µm space between 
each electrode.  Each electrode has 177 µm2 site area. On top of the electrodes of the 
experimental group, glial cells were plated to simulate the cellular encapsulation in the 
brain.  
The Petri-dish test chamber allowed us to make an in vitro cellular encapsulation 
model using glial cells, which form a cellular sheath around the implanted 
recording/stimulation electrode array.  Glial cells were kept aseptic in the test chamber 
while the electro-physiology (EP) tests were being performed to model encapsulation.  
For the EP tests using the stimulation/recording setup, three types of electrodes were 
placed in the test chamber: stimulation, recording and reference electrodes.  For the EP 
tests measuring impedances, three types of electrodes were placed in the test chamber: 
counter, recording and reference electrodes.  
2.2.2. Signal recording 
A differential recording method was applied to eliminate white noise as illustrated 
in Fig.3.4.  Experimental and control electrodes were used to investigate the actual effect 
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of encapsulation in signal quality.  Recording electrodes and the reference electrode of 
the recording system receive the signal transmitted by the stimulation electrodes. The 
received signals were processed using a differential amplifier (TDT, Tampa, FL) to 
eliminate white noise. These signals were recorded by a 32 channel simultaneous 
recording system: the experimental group had 16 channels of recording electrodes plated 
with glial cells and the control group had another 16 channels but without glial cells.  The 
reference electrode was used to eliminate white noise by differential recording.  A no-
leak Ag/AgCl reference electrode (Cypress systems, Chelmsford, MA) was used in order 
to prevent possible damage to living cells from the diffusion of the filling solution from 
the reference electrode into the PBS in the test chamber. 
 
 
Fig.3.4. The in vitro stimulation/recording setup was developed and validated to 
investigate the cellular encapsulation effect on the performance of recording electrodes.  
On top of the recording electrodes sitting at the bottom of the Petri-dish, glial cells were 
plated to model the in vivo cellular encapsulation.  Another recording electrode array with 
the same physical properties but without cell plating was used as the control electrodes 
(not shown in the figure).  Three types of electrodes were placed in the test setup: 
stimulation, recording and reference electrodes.  Recording electrodes and the reference 
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electrode receive the signal transmitted by the stimulation electrodes. The received 
signals were processed using a differential amplifier to eliminate white noise. 
 
To simulate the cellular encapsulation in the brain, the electrodes of the 
experimental group were plated with glial cells on top.  The rationale for glial cells was 
that the glial cells were suspected of hindering the signal transmission to the recording 
electrode. Two types of glial cells were used: primary astrocytes (Lonza, Switzerland), 
and meningeal fibroblasts (ScienCell, San Diego, CA) from adult male Sprague-Dawley 
rat cortices.  Cells were suspended and plated on the electrodes. All the recording 
electrodes were coated with bovine plasma fibronectin (20 µg/mL) before being plated 
with cells to promote adhesion of glial cells on the electrode surface.  Cells were cultured 
in DMEM supplemented with 10% fetal bovine serum (FBS) and antibiotics after being 
plated. The cells were kept in a humidified incubator at 37ºC and 5% carbon dioxide. 
Media was exchanged every 24 hrs. The temperature and the carbon dioxide level were 
maintained during the electro-physiology (EP) tests by performing each test in the 
incubator with electromagnetic shielding. Cell viability was ascertained by using a 
live/dead assay (Sigma-Aldrich, St. Louis, MO). Electro-physiology tests were conducted 
on days 1, 4 and 6 after seeding cells. Along with the recording electrodes for the 
experimental group, control electrodes were placed in the chamber and the same electro-
physiology tests were performed on them. The control electrodes had exactly the same 
configuration and were kept in the same condition as the experimental electrodes but 
without plated cells. 
The stimulator uses two types of stimulation signals: a single sine wave train and 
neuronal spike signals previously recorded from a rat brain.  The single sine wave train is 
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used to determine the electrode performance quantitatively whereas the neuronal spike 
signals are used to determine the electrode performance by a signal similar to that of an 
actual recording in vivo. This stimulation is performed using stimulation electrodes 
emerged in the PBS, which consist of two adjacent platinum wires (AM-systems, MO) 
with a diameter of 125 µm. These adjacent two-wire electrodes make dipole stimulation 
possible, where one electrode functions as a current source and the adjacent electrode 
functions as a current sink.  These dipole electrodes transmit a stimulation signal to be 
propagated in the test chamber and received by the recording system.  
First, recorded signals provided signal amplitude, noise amplitude, signal-to-noise 
ratio (SNR) and the capability to detect/cluster units. These parameters were used to 
investigate the effect of cellular encapsulation on the electrode’s recording performance.  
Impedance testing was performed using the above experimental setup to compare the 
impedance between bare electrodes (control) and glial cell-plated electrodes 
(experimental). Impedance tests of the electrodes were conducted using an Autolab 
potentiostat PGSTAT12 (Eco Chemie, Utrecht, The Netherlands) with a built-in 
frequency response analyzer software (Brinkmann, Westbury, NY).  For each impedance 
test, three types of electrodes were used: reference, recording, and auxiliary electrodes.  
The latter two electrodes were the same as those used as in the EP tests.  For the auxiliary 
electrode, a coiled platinum wire (125 µm diameter) was used. Impedance tests were 
conducted with sweep frequencies between 10 Hz and 10 kHz.  
2.2.3. Immunohistochemistry (IHC) 
Since we wanted to investigate the effect of encapsulation of glial cells on electrode 
performance, cells were fixed and imaged using an Immunohistochemical (IHC) process 
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at the end of the EP and the impedance tests to confirm the encapsulation visually.  Cells 
were fixed with 4% paraformaldehyde and then permeabilized with 0.5% Triton (Triton 
X-100, Sigma, St. Louis, MO). Next, cells were treated with primary antibodies in a 
blocking solution containing 4% goat serum for 12–18 hrs at 4 C. Antibodies were 
directed against GFAP, a marker of intermediate filaments, indicating reactive astrocytes 
(rabbit IgG, 1:1000, Dako, Carpinteria, CA).  In addition, vimentin, a marker of 
intermediate filaments, was used to stain the intermediate cytoskeleton of meningeal 
fibroblasts and astrocytes (mouse IgG1, 1:1000, Sigma, St. Louis, MO). Cells were then 
incubated with appropriate secondary antibodies (1:220) conjugated to either Alexa 488 
or Alexa 594 fluorescent dye (Molecular Probes, Eugene, OR) for 1 hr at room 
temperature. All cells were counterstained with DAPI (Molecular Probes) to identify cell 
nuclei. 
A linear regression model was employed for a statistical power analysis 1) to 
calculate the net effect of the cellular encapsulation on the impedance and 2) to determine 
if the impedance increases of the glial cell plated electrodes (experimental) are 
statistically significant. The impedance of an iridium electrode changes over time when 
the electrode is soaked in an electrolyte.  This impedance change is attributed to the 
change of the electrochemical interface between the electrode and the electrolyte.  
Because of this electrochemical change, it should be determined if the impedance 
increases of the experimental group is due to the effect of the plated cells or due to the 
change of the electrochemical interface.  To address this issue, we employed a linear 
regression model using the impedances of the control group as predictors and the 
impedances of the experimental group as dependant variables. This model used the 
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impedance data collected during the soak test before plating cells on the electrodes of 
experimental group.  For the soak test, both the experimental electrode array and the 
control electrode array were soaked in PBS for a week without plating cells on neither of 
these arrays and the impedance data were collected on daily bases. Then, the impedance 
data of these arrays were used to make the linear regression model that provides the 
expected impedance value of an experimental electrode based on the impedance values of 
the control electrodes on a given day. This expected impedance represents the baseline 
value under conditions, which consists of the electrochemical effect alone, without the 






3.1. Glial activation effect on impedance 
Our results confirmed that neural probe functionality begins to decrease at the early 
inflammatory stage.  Neural probes encapsulated by the activated glial cells by the injury 
model (thrombin/scratch) or the acute inflammation model (LPS) demonstrated higher 
impedance than the probes encapsulated by the inactivated cells (control). 
 
3.1.1. Impedance at 1 kHz 
Neural probes encapsulated with glial cells activated by the injury model 
(thrombin/scratch, experimental) demonstrated higher impedance at 1 kHz than the 
probes encapsulated by the inactivated cells (control) as shown in Fig.3.5.   
The group activated by the injury model (thrombin/scratch) demonstrated 
significantly higher impedance compared to the control group on day 1 (p<0.05, student’s 
t-test).  On day 5, there was no significant difference between two groups.  It is important 
to note that, as mentioned in method, we monitored the baseline impedance of bare 
electrodes to confirm the baseline impedance is constant during the period of experiment.  
The impedance of these bare electrodes was constant over five days.  As confirmed in the 
microscopic pictures (Fig.3.6) cells were confluent and viable during the impedance 






Fig.3.5. Activated glial cells by the injury model (thrombin/scratch) demonstrated higher 
impedance than control, which was subjected to the same condition except the treatment 
by thrombin/scratch.  The difference was significant on day 1 (p<0.05) but not on day5.  
Impedance was measured at 1 kHz and normalized to the value of day 1 control group. 
For each group, samples were from four independent conditions. 
 
 
Fig.3.6. Phase contrast microscopic pictures confirmed that glial cells on the setup were 
viable right before the impedance measurement.   
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3.1.2. Signature in the impedance spectra 
As Johnson et al. and Williams et al. observed in their in vivo studies, our in vitro 
results confirmed a ‘hump’ corresponding to massive encapsulations in the plotted 
impedance spectra (red line in Fig.3.7) (Johnson, Otto et al. 2005; Williams, Hippensteel 
et al. 2007).  These humps were observed by Johnson et al. using the same type of 
electrodes we did and by Williams et al. using other types of electrodes.  In the Nyquist 
plots (Fig.3.7), the electrode sites with encapsulation demonstrated a ‘hump’ (semi-
circular arc) in the high frequency range of the impedance spectra.  This hump was more 
pronounced with stronger encapsulation, for electrode sites of channels 4, 12, 5, 15, 2 and 
16.  The microscopic view (not shown) of these electrode sites confirmed that they were 
encapsulated by densely clustered cells.  However, this hump was not observed for less- 
or non-encapsulated electrode sites.  For bare electrodes at baseline (before cell plating), 
the Nyquist plots showed a linear relationship between the real and imaginary 
components (blue line in Fig.3.7). 
 
Fig.3.7. Heavily encapsulated electrode sites showed a ‘hump’ in the low frequency 
range (red) of the impedance spectra whereas bare or lightly encapsulated sites showed 
linear profile in the Nyquest plot (blue). Impedance spectra was conducted over 10, 16, 
47, 300, 650, 1000, 3000 and 5000 Hz to represent physiological frequencies. 
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3.2. Glial encapsulation effect on signal recording 
3.2.1. Impedance of the plated cells 
The initial impedances of the electrodes at 1kHz before plating cells were in good 
agreement with the values reported previously by other investigators.  As shown in Fig.2 
day -6, they were in the range of 1.0 Mohm and 1.6 Mohm for 90% of electrodes.  
Impedance, after the electrodes were soaked in phosphate buffered saline (PBS), 
dropped with time.  This impedance drop was dominant for the first two or three days and 
plateaued after four days in all electrode arrays.  The impedance changed with time for 
both control and experimental electrode arrays showing the same trend.  Hence the results 
confirmed the need for a mathematical model to predict the baseline impedance of the 
experimental electrodes (based on the control group impedance) on a given day.  Using 
the data from the soak test, we built a linear regression model that passes origin; the 
predictor was the mean of the impedances of the control electrodes and the dependant 
variable was the mean of the impedances of the experimental electrodes. The R-value of 
the model was 0.890 with n=4.  Then we built a model for each channel of the 
experimental electrodes; the predictor was the mean of the impedances of the control 
electrodes and the dependant variable was the impedances of each channel of the 
experimental electrodes. The R-value of the model for each channel ranged from 0.500 to 
0.990 with n=4. 
The impedances increased significantly after plating cells on the electrodes in the 
experimental group whereas this increase did not happen with the control group, i.e., 
without plated cells; Fig.3.8 shows the impedance over time course.  There was a 
significant difference; 1) between the control and the experimental group and 2) between 
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the expected impedances and the measured impedances of the experimental group. The 
impedance of the experimental group was higher than that of the control group by more 
than five standard deviations.  In addition, the measured impedance of the experimental 
group was significantly higher than the expected values generated by the linear regression 
model (see section 2.2.3). The difference was more than five standard deviations with 
p<0.001 by a paired student t-test in both cases. Fig.3.8(a) shows the daily impedance 
changes of the control and experimental electrodes over the entire duration of experiment.  
Fig.3.8(b) shows the measured impedance of the cell plated group (experimental) 
normalized to the expected impedance by the linear regression model (LRM).  The 
difference between the expected and measured impedance of an electrode represents the 
impedance increase caused solely by the plated cells.  Error bars in these figures 
represents the standard error of the mean (SEM). 
Some electrodes demonstrated impedance exceeding 5 Mohm as in an open circuit 
and other electrodes demonstrated impedance as low as 10 kohm as in a short circuit. 
These unusual impedance values were observed in both cell plated electrodes 
(experimental group) and bare electrodes (control group). These extremes in impedance 
were most likely due to device failure, not the effect of the plated cells on the electrode.  
Therefore, the data from these electrodes were excluded. 
3.2.2. Stimulation/recording 
The cells plated on the electrode increased the impedance and hence degraded the 
signal recording performance of the electrode. Electrode performance based on the signal 
amplitudes recorded from the single sine wave train is shown in Fig.3.9.  Fig.3.10 shows 
the measured signal amplitudes of the cell plated group (experimental) normalized to the 
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signal amplitudes by the linear regression model (LRM).  The difference between the 
expected and measured signal amplitudes represents the decrease of signal amplitudes 
caused solely by the plated cells.  Error bars in these figures represents the standard error 
of the mean (SEM).  The initial electrode performance in the bare electrodes (the control 
electrodes for the entire duration and the experimental electrodes before cell plating) 
showed the same trend of higher impedance coupled with lower performance as shown in 
Fig.3.8. An electrode with high impedance received the small amplitude of the 
stimulation signal and an electrode with low impedance received the large amplitude of 
the signal. After cells were plated on the experimental group, the impedance of these cell 
plated electrodes increased and hence these electrodes received smaller amplitude of the 
stimulation signal. 
The amplitude of the recorded signal in the cell plated electrode decreased on days 1 and 
4 and then plateaued at the value of day 4 (Fig 3.9). These increases between day 0 and 
each of the subsequent days were statistically significant with p<0.05 by paired student t-
test. 
3.2.3. Immunohistochemistry (IHC)  
The plated glial cells formed an evenly distributed tight cell layer on top of the 
recording electrodes.  The cell layers on the electrode array were constructed to model 
the in vivo encapsulation, with the fibroblast surrounding the electrode array and the 
astrocytes surrounding the fibroblast (Cui, Wiler et al. 2003) as shown in Fig.3.11(A) and 
(C).  The fibroblasts were first plated on the electrode array and then astrocytes in 24 hrs.  
Both of these cells were plated at the density of 1x106 cells/cm2; the fibroblasts were 
stained red and the astrocytes were stained green in Fig.3.11(C).   A microelectrode array 
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was located underneath of the cell layers but it failed to be visualized in the fluorescent 
microscopy because of the thick cell layer on top of it.  Fig.3.11(A) shows the phase 
contrast microscopic view of the cell layers on the electrodes.  Live/dead analysis showed 
that 90% of both cells in the cell construct on the electrodes were still viable after two 
weeks of in vitro EP tests.   
The maximum cell density we could plate on the electrode was 1x106 cells/cm2; at 
higher densities, the cell layer was delaminated from the electrode after approximately 
seven days of testing.  To determine the maximum cell density that could be achieved 
without delamination, glial cells with various densities, ranging from 1x104 to 1x106 
cells/cm2, were plated on test chambers.  This delamination is most likely due to 
insufficient nutrients and oxygen supplied to the cells on the bottom layer.  Live/dead 
analysis showed that more than 90% of cells were viable at cell densities equal to or 







Fig.3.8. Glial cells plated on the electrodes increased impedance in the in vitro setup to 
model cellular encapsulation in vivo.  The increase was observed in the cell plated 
electrode whereas there was no significant increase in the control electrodes with no cells 
(a).  In addition, there was a significant increase in impedance between before and after 
cell plating on the same electrodes (b); the impedances were normalized to the baseline 
value calculated by the linear regression model (LRM).  The error bars indicate the 
standard error of the mean. 
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Fig.3.9. Glial cells plated on the electrodes degraded signal recording performance of the 
electrode compared to the control electrodes with no cells.  The recording performance 
was assessed based on the recorded signal amplitude of the single sine wave train.   The 
signal amplitude increased significantly after plating cells whereas there was no 
significant increase in the control electrodes.  This increase was also demonstrated in the 
recording of the simulated neuronal spike; upper plot was recorded from the cell plated 
electrode whereas lower plot was recorded from the control electrode with no cells.  Both 




Fig.3.10. There was a significant degradation in the signal recording performance 
between before and after glial cell plating on the same recording electrode.   The signal 
amplitude increased significantly after plating cells on days 1, 4 and 6.  The signal 
amplitudes of the cell plated electrodes were normalized to the baseline value calculated 
by the linear regression model (LRM).  These increases were also demonstrated in the 
recording of the simulated neuronal spike; lower plot was recorded before cell plating 
and the upper plot was recorded after cell plating from the same electrode.  Both of the 








Fig.3.11. The plated glial cells formed an evenly distributed tight cell layer on top of the 
recording electrodes.  Phase contrast micrograph shows the high density living cell layer 
on the recording electrodes (A) vs. control electrodes without the cell layer (B).  
Fluorescent micrograph illustrates that the plated cells were evenly distributed over the 
cell layer (C): 1) meningeal fibroblasts and astrocytes were stained green by vimentin 
counterstaining, 2) reactive astrocytes were stained red by GFAP counterstaining, and 3) 
cell nuclei were stained blue by DNA staining using Hoechst.  The recording electrode 





4.1. Glial activation effect on impedance 
Although previous in vivo studies were able to provide valuable observations about 
the increasing impedance over the duration of neural probe implantation, it was not clear 
whether the impedance increase was directly due to the activation of the glial cells.  This 
impedance increase by activated glial cells in the early inflammatory stage is consistent 
with in vivo impedance increase in the first 3-4 days post implantation (Ludwig, Uram et 
al. 2006).  
Since we learned that the neural probe functionality decreases with the glial 
activation in the early inflammatory stage, the next question is how to mitigate the 
inflammation cascade.  Possible solutions may involve the introduction of thrombin 
inhibitors, proinflammatory cytokine inhibitors, or antiinflammatory drugs such as 
corticosteroids at the probe site.  
The signature hump in the impedance spectra that is documented in our study and 
prior in vivo studies could be used as a hallmark in non-invasively detecting glial 
encapsulation providing a crucial tool for the dynamic control of glial encapsulation 
necessary for the SRNP (see chapter 1). 
The fact that the relative impedance of the injury group (thrombin/scratch) on day 5 
was not significantly higher than the control group suggests that the effect of injury 
(thrombin/scratch) on impedance is the greatest at the early stage of inflammation.  This 
effect may be due to: 1) the activity of cells on day 5 might not be as good as on day 1 
due to the fact that cells were in the low serum media (1% FBS) for five days.  They may 
not have had sufficient nutrients for survival.  Therefore the intercellular adhesion 
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became weak and increased electrical permeability. 2) The activation effect by thrombin 
might be terminated between day 1 and day 5 and no additional activation occurred.  We 
suspect that once an activation effect terminated, intercellular adhesion became weaker.  
Additional activation might not have occurred after day 1 because thrombin may have 
degraded after day 1 due to the short half-life, about 35 min (3 NIH U/mL at 37ºC) 
(Leborgne and Graber 1994).  This short half-life of thrombin also explains the smaller 
expression of some cytokines, CTACK, GM-CSF, IL-2, IL-4, KC, and MCP-1 on day 5 
than on day 1 (see protein array results in chapter 2). 
The higher impedance in the activated glial cells could be due to the up-regulated 
intercellular adhesion molecule-1 (ICAM-1).  During the early inflammation stage, the 
activated astrocytes are recruited to the implanted neural probe and form tight 
intercellular adhesion (Turner, Shain et al. 1999; Szarowski, Andersen et al. 2003).  In 
astrocytes and microglia, the expression of intercellular adhesion molecule-1 (ICAM-1), 
a mediator of cell-cell and cell-extracellular matrix (ECM), is enhanced by 
proinflammatory cytokines such as TNF-alpha, IL-1beta, IFN-gamma or also by LPS 
(Frohman, Frohman et al. 1989; Merrill and Benveniste 1996; Lee and Benveniste 1999).  
We hypothesized that the ICAM might induce tight astrocyte-astrocyte and/or astrocyte-
electode adhesion.  These tight adhesions may form a tight seal between astrocyte cells 
and between asstrocyte and electrode surface, resulting in prevention of the ion diffusion 
across the cell layer and hence attenuate the signal conduction.  One good indicator of the 
signal conduction across the cell layer is the impedance across it.  Vetter et al. observed a 
correlation between the impedance and recorded signal quality in vivo (Vetter, Williams 
et al. 2004; Ludwig, Uram et al. 2006).  When the impedance of the electrodes was high, 
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signal to noise ratio (SNR) was low.  Giaever and Merrill demonstrated that MDCK cells 
with tight intercellular adhesion showed significantly higher impedance across the cell 
layer in vitro (Giaever and Keese 1993; Merrill and Tresco 2005).   
Although LPS induces morphological change from ramified to amoeboid as 
observed by Beck et al. in cultured mouse microglia (Fig.2.15) (Beck, Penner et al. 2008), 
the effect of microglial shape change on the impedance is assumed to be small because 1) 
the portion of microglia in our culture was small (less than 20%) and 2) microglia may 
not directly adhere to the electrode surface since they sit on top of astrocytes in a mixed 
culture (Saura 2007). 
 
4.2. Glial encapsulation effect on signal recording 
In this paper, we introduced and demonstrated the capability of an in vitro 
stimulation/recording setup to model the in vivo cellular encapsulation.  By using this 
setup, we could record simulated signal through the recording electrodes and evaluate the 
performance of the encapsulated electrodes by analyzing the recorded signal. 
With the cellular encapsulation, the performance of the electrodes degraded, as 
confirmed by both increased impedance and decreased recorded signal quality.  In 
addition, in the recorded neuronal spike signals, not only the amplitude of the spikes was 
smaller but also they were less discernable in signal received by the cell plated electrodes 
than by the control group.  We suspect the reason for the impedance increase and the 
signal amplitude decrease on the two initial measurements (days 1 and 4) is due the 
progression of the cell attachment to the electrode and the formation of intercellular 
adhesion between the plated glial cells.  This phenomenon hinders electrical signal 
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transmission through the electrical double layer at the electrode and the electrolyte 
interface.  Therefore, specifically, the impedance increased and the signal quality 
decreased.  On the other hand, the plateauing of the impedance and the signal quality 
after day 4 is most likely due to cell confluence; whereas, the small fluctuations observed 
in this plateau (Fig 3.8 and Fig 3.9) is most likely due to the metabolite and movement of 
living cells on the electrodes. 
Day to day fluctuation of the impedance and the recorded signal quality due to the 
electrochemical effect reconfirmed the importance of the linear regression model.  For 
example, the impedance of the experimental group increased between days 4 and 6, 
however, the impedance decreased in the control group (Fig 3.8).  The impedance 
increase in the control group whereas the decrease in the experimental group indicates 
that there was a big increase in impedance due to the electrochemical effect (on both 
experimental and control group) and was a small decrease in impedance due to the cell 
plating effect (only on the experimental group).  We could determine the net effect of cell 
plating using the LRM otherwise we could have misinterpreted the cell plating effect.  In 
addition, the similar tendency of the two electrode arrays in impedance and the recorded 
signal amplitude during the soak test before plating cells as shown by the high r-square 
value (0.900) in the LRM made it possible to build the LRM to calculate the baseline 
value for the experimental group with reasonable accuracy. 
The sensitivity of this in vitro stimulation/recording setup makes it possible to 
quantify the effect of encapsulation and distinguish this effect from electrochemical 
effect or other artifact.  After plating cells on the electrode arrays, the impedance 
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increased and the signal quality degraded significantly.  The statistical significance was 
more than eight standard error of the mean.    
The in vitro stimulation/recording setup proved that impedance and recorded signal 
quality data can be used to quantify the encapsulation.  This method, therefore, can be 
used in vivo as well to determine the presence and the degree of encapsulation so that 
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DYNAMIC CONTROL OF GLIAL ACTIVATION: 
AN IN VITRO MODEL 
1. Introduction 
Signal quality for long term stable recording and stimulation is challenged by the 
low electrical conductivity of glial encapsulation.  Efforts made to intervene in this 
encapsulation problem include injecting voltage pulses (rejuvenation) and delivering 
corticosteroid systemically and locally (Johnson, Otto et al. 2005; Spataro, Dilgen et al. 
2005).  These therapeutic agents have been shown to reduce the tissue reaction. 
 In this study, we propose a concept of a new local drug delivery system with 
feedback control for dynamic control of the neural environment termed ‘Self-Repairing 
Neural Probe (SRNP)’ (Fig. 4.1 and Fig. 4.2) (Moon, Pellinen et al. 2007).   The 
controller of the SRNP will sense the level of encapsulation using its non-invasive 
sensing method and then will compare the sensed encapsulation level with the target 
encapsulation level to maintain the desired signal quality of neuronal recording or 
stimulation given by input value.  If the sensed encapsulation level is higher than the 
target encapsulation level, the controller will inject inactivation agents to reduce the 
encapsulation, which in turn will prevent reduced signal quality for recording or 
stimulation.   
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Fig. 4.1. Concept diagram of the self-repairing neural probe.  The controller will sense 
the level of encapsulation using its non-invasive sensing method and then will compare 
the sensed encapsulation level with the target encapsulation level to maintain the desired 
signal quality of neuronal recording or stimulation given by input value.  If the sensed 
encapsulation level will is higher than the target encapsulation level, the controller will 
inject drugs to reduce the encapsulation level and thus acquires desired signal quality for 
recording or stimulation. In order to build this feedback controlled drug delivery system, 
two major components are required; sensing part and actuation part.  Also we need, 
neural probe with fluid delivery capability. 
 
 
Fig. 4.2. Concept illustration of the implanted self-repairing neural probe (SRNP).  The 
drugs will be delivered locally to the tissues on demand.  This local and temporal drug 
delivery is expected to maximize drug effect whereas minimizing possible toxic effect 
caused by high drug dosage.  
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Fig. 4.3. The proof of concept for the dynamic control of the encapsulation level through 
sequential activation/deactivation of glial cells over a short period of time. The sequential 
activation/deactivation is conducted every 24 hrs and impedance was measured in 24 hrs 
after applying each activation/deactivation agents. 
The dynamic control capability is crucial to realize the self-repairing neural probe 
(SRNP).  The activation level had to be controlled in a short period of time to obtain 
stable recordings.  Nelson et al. demonstrated that astrocyte culture from mouse brain 
changed their morphologies when these cells were sequentially treated with thrombin and 
dbcAMP in a short period of time (Nelson and Siman 1990).  Giaever et al. demonstrated 
that the morphology change of cells on an electrode changed the impedance of the 
electrode (Giaver 1993). 
In this study, we demonstrate the proof of concept for the dynamic control of the 
encapsulation level through sequential treatments of glial cells with LPS in 10% FBS and 
dbcAMP in 0% FBS over a short period of time.  For each step of the treatment, we 
investigated the effect of the change of the encapsulation levels on probe functionality by 
monitoring their impedance.  The sequential treatments are conducted every 24 hrs and 
impedance was measured in 24 hrs after applying each treatment agent (Fig. 4.3).   
77 
In addition, we introduce a local drug delivery system for dynamic control of neural 
environment using parylene-based microelectrodes with a microchannel for drug delivery.  
In order to build the SRNP, two major functions are required; sensing and actuation 
(control) of glial encapsulation.  The sensing encapsulation, using impedance spectra, 
was demonstrated in chapter 3.  For the control of encapsulation, we need a local drug 
delivery system to deliver inhibition agent to the place where the encapsulation occurred.  
We can deliver liquid phase agents using the microchannel and, by using hydrophilic 
polymer-based nanopoarticles, water insoluble drugs can be loaded in the nanopoarticles 
and delivered in aqueous emulsion.  Also, NP-based release mechanisms enable sustained 
drug release demonstrated to be important by Spataro and colleagues to suppress the 
sustained reactive response (Spataro, Dilgen et al. 2005).  We propose releasing DEX by 
diffusion from the microchannel, which is filled with NPs containing DEX.  As the NPs 
are too large and heavy to be transported by diffusion, only the released DEX from NPs 
will be diffused to the brain tissue (Nicholson 2001).  The long (15 mm) and narrow (40 
μm x 5 μm) microchannel gives time to transport DEX to the outlet port of the channel.  
The DEX near the outlet port will diffuse immediately after release from the NPs.  
However, it will take time for DEX loaded far inside the channel to be released and 





2.1. Dynamic control of glial activation 
To demonstrate the proof of concept for the dynamic control of the glial 
encapsulation level, we developed a model that can treat glial cells sequentially with LPS 
in 10% FBS and dbcAMP in 0% FBS and monitor their impedance over a short period of 
time using the impedance monitoring setup described previously (chapter 2).   
2.1.1. Experimental setup 
Primary glial cells were isolated from fetal mouse brain and plated on a 75 cm2 
tissue culture treated flask as described in chapter 2.  These cells were allowed to grow 
and proliferate for 2-3 weeks based on the state of confluence and then plated on the 
experimental setup that can monitor impedance as previously described (see chapter 3for 
more details).  These cells were initially plated and cultured in 10% FBS media followed 
by the treatment with dbcAMP (1mM in 0% FBS for 24 hrs).  Then cells were treated 
with LPS (10 µg/mL in10% FBS for 24 hrs).  Finally cells were treated again with 
dbcAMP (1mM in 0% FBS for 24 hrs).  
 
2.1.2. Morphological change of glial cells due to sequential treatments with 
LPS in 10% FBS and dbcAMP in 0% FBS  
To confirm the morphological change of glial cells induced by the sequential 
treatments with LPS in 10% FBS and dbcAMP in 0% FBS, before testing the effect of 
the sequential treatments on impedance, sequentially treated glial cells were monitored 
their morphologies using high magnification phase contrast microscopy.  Phase contrast 
microscopic pictures of living cells were taken at the end of each treatment periods. 
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2.1.3. Impedance measurement 
Mixed glial cells were plated on a 24-well cell culture plate and treated with LPS in 
10% FBS and dbcAMP in 0% FBS sequentially for 24 hr periods.   Impedance at 1 kHz 
was monitored at the end of each treatment period.   We used the same protocol used in 
chapter 3 for the impedance measurements.  Briefly, three electrodes were used to 
measure the impedance: working (microelectrodes), counter (platinum-iridium coil), and 
reference (miniature Ag/AgCl).  HBHS was used as an electrolyte.  Phase contrast 
microscopic pictures were taken right before the impedance measurements to confirm 
that the cells were confluent and viable during the impedance measurements.   
 
2.2. Local drug delivery system for dynamic control of neural environment using 
parylene-based neural probe  
The drug delivery system to be used for the SRNP should be able to deliver 
inhibition agent to the exact same tissue where the encapsulation occurred to maximize 
the efficacy of the drug to the target tissue and, at the same time, minimize the toxicity to 
the surrounding tissue.  To meet this requirement, we developed a local drug delivery 
system using the multifunctional neural probe with recording and fluid delivery 
capabilities previously developed in our lab by Pellinen (Pellinen, Moon et al. 2005). 
2.2.1. Fluid delivery neural probe 
The fluid delivery probe used in this study was designed and fabricated by our 
group at the Neural Engineering Lab at the University of Michigan (Pellinen, Moon et al. 
2005).  It is a microfabricated, multi-channel polymer probe capable of selectively 
delivering chemicals at the cellular level as well as electrically recording and stimulating 
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neurons in vivo.  The width and height of the fluidic channel are 40 µm and 5 µm, 
respectively.  The electrical recording sites are located on the top side of the probe − 
designed to function for both electrical recording and stimulation (Fig. 4.4).  The probe is 
mounted on a custom-built printed circuit board (PCB) with integrated electrical 
connections.  The probe is ball-bonded onto the PCB (Meyer, Stieglitz et al. 2001), on 
which an electrical connector (Omnetics Connector Co., Minneapolis MN) is soldered.  
This assembly gives electrical connection between the electrode sites on the microprobe 
and the electrical signal recording system (Plexon Inc., Dallas, TX).  The electrical 
recording functionality was previously tested and verified as shown in Fig. 4.5. 
 
 
Fig.4.4. (A) Photograph view of the flexible parylene-based microfluidic electrode.  The 
total thickness of the device is nominally 20 µm, with a channel height of 5 µm. (B) 
Photograph taken during implantation of two neural probes in a rat model.  Shown are 
two neural probes connected to PCBs mounted with Omnetic nano-connectors®. The 
dura has been resected prior to the implantation. (C) Rat skull with two neural probes 





Fig.4.5. Recording capabilities of the neural probe demonstrated with data snapshots: 
waveforms, raw data samples, and action potentials of 3 different units on 3 different 




Access to the flow channel is provided through a polyimide tube (A-M systems, 
Inc.).  The flow is driven by a volume flow controlled syringe pump (WPI 
UltraMicroPump) and a micro syringe (SEG 5 µL).  The fluid is initially filtered through 
a 0.22 µm in-line filter (Corning, Inc.) to remove trace particulates.  The connection 
between the outlet of the syringe and the inlet port of the microprobe is made by 
polyimide tubing with a 100-µm inner diameter.   The fluid enters the inlet port of the 
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microprobe, and flows through the microchannel inside of the probe until it comes out 
through the outlet ports, which are placed at the tip of the probe as shown in Fig.4.4.  
High performance liquid chromatography (HPLC) grade water was injected to visually 
validate the fluidic line in the device-assembly.  If the fluidic line has no clogging or 
leakage, a water bubble appears at the outlet port of the probe.  These outlet ports are 
placed at the tip of the probe as shown in Fig. 4.4. 
2.2.3. Drug embedded nanoparticle 
Poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with dexamethasone 
(DEX) were prepared by an oil-in-water emulsion/solvent evaporation method (Arshady 
1991; Song, Labhasetwar et al. 1997; Jain 2000).  PLGA was dissolved in a 
dichloromethane (DCM) in 5.3% (w/v) and DEX was dissolved in acetone in 1.3% (w/v).  
These two organic solutions were mixed together.  Then, the mixed solution was added to 
a 5% (w/v) poly(vinyl alcohol) (PVA) in deionized (DI) water solution.  The mixture 
underwent sonication to form an oil-in-water type emulsion by a probe type sonicator 
(Ultrasonic processor, CP-750, Cole Palmer).  Power of the sonicator was kept at 60 W 
for 10 min.  The emulsion was stirred gently to allow evaporation of the organic solvents 
over 12 hrs.  Nanoparticles were collected by ultracentrifugation at 35,000 rpm for 1 hr 
(Beckman Couler Optimal L-90K, Beckman, Arlington Heights, IL).  The collected 
nanoparticles were washed three times with DI water to remove PVA residue and 
unreacted drug.  The final product of DEX loaded PLGA nanoparticles were collected by 
lyophilization (Freezone 4.5, Labcono co., MO).  
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3. Results 
3.1. Dynamic control of glial activation 
We demonstrated the concept for the dynamic control of the encapsulation level 
through sequential treatments of glial cells with LPS in 10% FBS and dbcAMP in 0% 
FBS over a short period of time as shown in Fig.4.6.   
3.1.1. Morphological change of glial cells due to sequential treatments with 
LPS in 10% FBS and dbcAMP in 0% FBS  
Cells treated with LPS in 10% FBS were flat in shape and showed less intercellular 
space whereas cells treated with dbcAMP in 0% FBS showed thinner processes and more 
intercellular space as shown in Fig 4.6. This pattern was clearly pronounced during the 
sequential treatments: (1) cells treated with dbcAMP in 0% FBS on day 1 showed stellate 
shape (Fig. 4.6(a)), (2) cells treated with LPS in 10% FBS on day 2 was flat shape (Fig 
4.6(b)), (3) cells treated with dbcAMP in 0% FBS again on day 3 became stellate again 
(Fig. 4.6(c)), and (4) cells treated with LPS in 10% FBS again on day 4 became flat again 
(Fig. 4.6(d)).  This data confirms that sequential treatments of glial cells with LPS in 10% 
FBS and dbcAMP in 0% FBS induce sequential morphological changes. 
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Fig.4.6. Sequential morphological change of glial cells due to sequential treatments of 
glial cells with LPS in 10% FBS and dbcAMP in 0% FBS: (a) cells were treated with 
dbcAMP (1mM in 0% FBS for 24 hrs), (b) then cells were treated with by LPS (10 
µg/mL in10% FBS for 24 hrs), (c) cells were treated with dbcAMP (1mM in 0% FBS for 
24 hrs) again, (d) cells were treated with LPS (10 µg/mL in10% FBS for 24 hrs) again. 
  
3.1.2. Impedance 
Impedance and the sequential treatments with LPS in 10% FBS and dbcAMP in 0% 
FBS demonstrated correlation (Fig.4.7): impedance (1 kHz) increased when cells were 
treated with LPS in 10% FBS and decreased when cells were treated with dbcAMP in 0% 
FBS except on days 3 and 4 of the sample in Fig.4.7 (a).  Glial cells were plated and 
cultured in 10% FBS media until they become confluent and then treated with LPS 
(10µg/mL)  in 10% FBS and dbcAMP (1mM) in 0% FBS sequentially.  Three 
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independent probe samples were tested: (a), (b) and (c).  Greater impedance changes 
were found in probe (a), which had the highest cell density.  This impedance-treatment 
correlation varied among different electrode sites in a probe as well as among different 
probes.  This may be due to either overcrowding of the cells in areas of dense 
encapsulation or sparce cell coverage in low density areas.  We suspect that when cells 
are overcrowded, impedance may not drop even when they are treated with dbcAMP in 
0% FBS.  On the other hand, when cells are sparce in an area, impedance may not 
increase even when they are treated with LPS in 10% FBS.  However, an important factor 
to demonstrate this ‘dynamic control of glial activation’, we found, is to have more than 
critical mass of cells encapsulating the probe because there should be enough population 
of cells to make intercellular interaction as previously observed by Nelson and Siman in 
their in vitro study (Nelson and Siman 1990).  Inserted pictures of Fig.4.7 show the cell 
morphology immediately before the impedance measurement of each period of treatment 
with LPS in 10% FBS or dbcAMP in 0% FBS.  As confirmed in the microscopic pictures 
cells were confluent and viable during each impedance measurement.   
Serum also induced higher impedance.  Glial cells treated with 10% serum showed 
higher impedance than the groups treated with 1% FBS (Fig.4.8).  Glial cells were plated 
on day -2 and cultured in 10% FBS media between days -2 and 0.  Then the cells were 
treated with either 1 or 10% FBS on day 0.  The cells treated with 10% FBS showed 
higher impedance than the cells treated with 1% FBS.  In addition, please note that the 
impedance of 1% FBS group dropped dramatically between days 0 and 1 (see Fig. 4.8) 
when the treatment condition was changed from 10% to 1% FBS.  This impedance drop 
is most likely due to the morphological change from flat to stellate induced by the 
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treatment with low serum media (1% FBS).  In both groups, impedance increased after 
encapsulation by more than 2 folds and then plateaued up to day 6.  This plateau of 
impedance between days 1 and 6 indicates that our injury model was reliable up to day 6 
in both cell layer and electrode surface.  Please note that cells used for 10% FBS group 
was rat astrocytes and fibroblast and for 1% FBS group was mixed mouse brain cells.  
However, because 1) most of genes are shared between mouse and rat, and 2) in both 
models, dominant cell type is astrocytes.  Therefore, we can deduce the trend of serum 
effect on impedance. 
 
Fig.4.7. Impedance and the sequential treatments with LPS in 10% FBS and dbcAMP in 
0% FBS demonstrated correlation: impedance (1 kHz) increased when cells were treated 
with LPS in 10% FBS and decreased when cells were treated with dbcAMP in 0% FBS 
except on days 3 and 4 of the sample (a).  Glial cells were plated and cultured in 10% 
FBS media until they become confluent and then treated with LPS (10µg/mL)  in 10% 
FBS and dbcAMP (1mM) in 0% FBS sequentially.  Three independent probe samples 
were tested: (a), (b) and (c).  Greater impedance changes were found in probe (a), which 
had the highest cell density. 
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Fig.4.8. Higher serum induced higher impedance.  Glial cells were plated and cultured in 
10% FBS media between days -2 and 0.  Then the cells were subjected to 1% FBS media 
(blue line) or 10% FBS media (red line) on day 0.  Please note that cells used for 10% 





3.2. Local drug delivery system for dynamic control of neural environment using 
parylene-based neural probe  
3.2.1. Microfluidics 
Fig.4.9 shows a sequential process of a water bubble growing at the fluidic outlet 
port of the polymer microprobe.  HPLC grade water from the syringe pump passed 
through the fluidic channel in the microprobe and came out through the outlet port of the 




Fig.4.9. Water delivered through a microfluidic neural probe. Figure A shows the whole 
electrode, up to the bonding pads.  The fluid connection (not shown) is to the far left of 
the probe.  Figure B shows the implant portion of the electrode prior to fluid delivery.  
Figure C show the initiation of flow, which quickly develops into a large bubble of fluid 
in Figure D. 
89 
 
3.2.2. Drug embedded nanoparticle 
Fig 4.10 shows scanning electron micrograph (SEM) of poly(lactic-co-glycolic acid) 
(PLGA) nanoparticles (NPs) loaded with dexamethasone (DEX) fabricated in neural 
engineering lab.  The NPs were prepared by an oil-in-water emulsion/solvent evaporation 
method.  A box in the picture illustrates the cross sectional size of the microchannel 
where the NP will be filled.  
 
 
Fig.4.10. Scanning electron microscopy (SEM) picture of the dexamethasone (DEX) 
embedded nanoparticles (NPs).  The red box in the picture illustrates the cross sectional 




We have successfully demonstrated the proof of concept of dynamic control of glial 
encapsulation, which is an essential element to realize the SRNP.  Although the 
correlation of our impedance results to probe encapsulation only represent the initial 
stage in dynamic control of encapsulation, in the long run, this dynamic control could 
mark the actuation points for the ‘Self-Repairing Neural Probe (SRNP)’ to reduce the 
encapsulation maintaining it within an acceptable range for stable signal recording or 
stimulation.  
Glial activation should not only be mitigated at the early stages but also throughout 
the entire period of probe use to counteract chronic tissue irritation caused by 
micromotion.  This chronic irritation is hypothesized to induce inflammation and activate 
glial cells (Subbaroyan, Martin et al. 2005). 
Since we wanted to achieve morphological changes in a short period of time, we 
used dbcAMP (1mM) in 0% FBS to induce stellate shape and LPS (10 µg/mL) in 10% 
FBS to induce flat shape for glial cells.  It could be argued, however, that serum could 
have more roles in morphological changes: cells might have become flat by high (10%) 
serum contents and have become stellate by no serum contents.  Nonetheless, since the 
goal of this study was to differentiate the impedance between different cell shapes in a 
short period of time, we wanted to create a set of environments for extreme shifts in cell 
shapes.  To provide more physiological conditions, future studies should include proper 
pairs of inhibitors and activators such as hirudin/thrombin or proinflammatory cytokines 
and their inhibitors in a media with the same serum contents. 
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Parylene based neural probe with microfluidic channel as well as electrical 
recording/stimulation sites was successfully fabricated and tested for electrical and fluidic 
functionality in early stage design.  Fluidic functionality test showed that the neural probe 
is sufficiently robust to be used for immediate drug delivery using liquid phase water 
soluble drugs.  NPs were successfully fabricated for Sustained drug delivery using drug-
loaded NP-mediated delivery.  This feedback controlled drug delivery strategy also could 
be applied for therapeutic drug delivery application. 
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CHAPTER V 
CONCLUSION AND FUTURE DIRECTION 
 
The in vitro models developed in the course of our investigation into the correlation 
between signal degradation and glial cell encapsulation of neural probes provided 
evidence of decreasing neural probe functionality with the glial activation, that is, at the 
very earliest stage of the inflammatory process.  Neural probes encapsulated by the 
activated glial cells activated in the injury model (thrombin/scratch) or the acute 
inflammation model (LPS) demonstrated higher impedance than the probes encapsulated 
by the inactivated cells (control). Armed with the evidence of when to intervene in the 
inflammatory cascade, the next question is how to mitigate the process.  Possible 
solutions may involve the introduction of thrombin inhibitors (hirudin and protease-
activated receptor-1 (PAR-1) antagonists), proinflammatory cytokine inhibitors 
(interleukin-1 receptor antagonist (IL-1RA) and soluble tumor necrosis factor receptor 
fusion protein (sTNFR:Fc)), antiinflammatory cytokines (IL-10), or antiinflammatory 
drugs such as corticosteroids (dexamethasone) at the probe site (Stone and Hofsteenge 
1986; Eisenberg, Brewer et al. 1991; Balasingam and Yong 1996; Paris, Hickey et al. 
1997; Assuma, Oates et al. 1998; Dinarello 1999; Greinacher, Volpel et al. 1999; He, 
Smith et al. 2005; Spataro, Dilgen et al. 2005).  In addition, we can test low dose of 
thrombin preconditioning during probe insertion, which reduced inflammation and 
prevented neuronal death induced by intracerebral hemorrhage (Hua, Keep et al. 2003). 
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Among these deactivation agents, we are more interested in thrombin/cytokine 
inhibitors rather than steroids because the effect of the inhibitors is specific in blocking 
the inflammation, therefore, less disrupting the immune system.  To block the 
inflammation chain reaction initiated by the proinflammatory cytokines, we should know 
which cytokines to target specifically.  This specific targeting is important not only to 
maximize the efficacy of the inhibitors but also to minimize undesired side effects.  In 
addition, we should know how much cytokines and thrombin are secreted to determine 
the amount of the inhibitors to be used.  Therefore identifying and quantifying the 
cytokines and, also, quantifying thrombin secreted due to the injury are very important. 
To identify/quantify cytokines and quantify thrombin, we need to collect and 
analyze the tissue around the probe insertion site in vivo.  The tissue need to be collected 
and analyzed at different time points to get temporal resolution of the expressed 
cytokines.  Takamiya et al. observed the inflammatory cytokine secretion caused by a 
traumatic brain injury (Takamiya, Fujita et al. 2007).  This temporal trend would be a 
good reference to the cytokine secretion caused by the injury due to the neural probe 
insertion.  We propose a method: (1) insert neural probes in the brain of animals, (2) 
collect the tissue around the probe at different time points (30min and 2, 4, 8, 24, 48, 72 
and 168 hrs), matching the time scale of cytokine expression, (3) homogenize the tissue 
to get tissue lysates, (4) analyze the tissue lysates with protein array to screen the 
expressed cytokines, and (5) analyze the tissue lysates with ELISA to quantify the 
selected cytokines based on the protein array analysis. 
Although blocking inflammation by thrombin/cytokine inhibitors has advantages 
over steroids, we should note that it might not be as effective as steroids.  Since the 
99 
inflammation cascade is hypothesized to depend on multiple pathways, blocking just one 
pathway by a specific cytokine inhibitor might not be enough to block the whole 
inflammation cascade, which can proceed through another pathway.  Therefore, to 
achieve better efficacy, the efforts should be made to block all the cytokines and 
thrombin, which involve the inflammation reaction, avoiding interference between 
inhibitors. 
We proposed and verified a novel tissue injury model to activate glial cells, which 
simulates both mechanical injury and the micro-hemorrhage by the blood vessel rupture.  
Our results demonstrated that glial cells were well plated on the electrode in the 
experimental setup and successfully activated.  We were able to create both injury 
(thrombin/scratch) and acute inflammation (LPS) models that mimic the in vivo 
conditions of neural probe insertion associated with glial activation.  The activation 
observed in our models confirmed the results of previous studies, i.e., that the glial 
activation induces morphological change and up-regulated inflammatory cytokine 
expression.  These models are expected to be used for further in vitro glial activation 
studies.   
The signature hump in the impedance spectra that is documented in our study and 
prior in vivo studies could be used as a hallmark in non-invasive and real-time 
assessment of reactive tissue reaction.  We could more precisely assess the glial 
encapsulation if we employ an equivalent circuit model fit to impedance spectroscopy 
data (Johnson, Otto et al. 2005; Williams, Hippensteel et al. 2007).  By using this model, 
we can extract the resistive components (Rex and Ren in Fig.5.1) of the encapsulation 
layer, which are responsible for the impedance increase and precisely represent the signal  
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Fig.5.1. The equivalent circuit model fit to impedance spectroscopy data included an 
iridium microelectrode, an adsorbed resistive layer, and a reactive glial layer.  The model 
includes a sealing resistance (Ren), describing protein adsorption and in some cases a 
layer of connective tissue.  In addition, the model incorporated adjacent cellular layers of 
glia and macrophages given by a membrane capacitance (Cm), a membrane resistance 
(Rm) and cellular membrane area (Am) from (Johnson, Otto et al. 2005) 
 
loss due to the encapsulation layer.  By using these resistive components, along with the 
signature hump, we could determine and quantify the glial encapsulation around the 
neural probe. 
 
We demonstrated the concept for dynamic control of encapsulation level by 
sequential activation/deactivation of glial cells over a short period of time as shown in 
Fig 4.5.  Although the correlation between the progress of impedance  and probe 
encapsulation represent only the initial stage in dynamic control of encapsulation, in the 
long run, this dynamic control could mark the actuation points for the ‘Self-Repairing 
Neural Probe (SRNP)’ to reduce the encapsulation maintaining it within an acceptable 
range for stable signal recording or stimulation.  Now we would like to move forward to 
the dynamic control of reactive tissue reaction in vivo.  We could test the concept of the 
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self-repairing neural probe using the prepared local drug delivery system.  After 
implanting a neural probe, watching encapsulation level by monitoring impedance 
spectra and inject inhibitors at optimal time points to reduce the encapsulation.  The 
reduced encapsulation will be monitored in real-time.  Ultimately, we could maintain the 




Fig. 5.2. Imaginary plot of dynamic control of glial activation.  The goal of this control is 
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